logo-loader

Emyria's Michael Winlo updates on new product launches

Published: 00:24 10 Dec 2020 GMT

Emyria Ltd's (ASX:EMD) Michael Winlo talks Proactive's Andrew Scott through its product launch update for December. They're working on two treatments independently - one for mental health and the other for IBS. The company has identified that 60% of its patient and 4.8 million Australians are impacted by mental health issues which cost the Australian health system $60 billion per year, so there is a market opportunity in a cannabis product for mental health – particularly with the increase in demand for new treatments during the COVID-19 pandemic.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

53 minutes ago